Custopharm, a U.S.-based provider of generic injectable products, has acquired two paragraph IV abbreviated new drug application (ANDA) products from Perrigo (www.perrigo.com). The company has attained full-ownership rights to acetaminophen injection and testosterone undecanoate injection. Acetaminophen is indicated for the management of mild to moderate pain and reduction of fever in the clinical setting. Testosterone is indicated for testosterone replacement therapy in adult males. “Both...